MCID: EPT009
MIFTS: 20

Epithelioid Cell Synovial Sarcoma

Categories: Cancer diseases

Aliases & Classifications for Epithelioid Cell Synovial Sarcoma

MalaCards integrated aliases for Epithelioid Cell Synovial Sarcoma:

Name: Epithelioid Cell Synovial Sarcoma 12 14
Synovial Sarcoma, Epithelioid Cell 12 69
Epithelioid Synovial Sarcoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5494
NCIt 47 C4278
SNOMED-CT 64 56422000
UMLS 69 C0334506

Summaries for Epithelioid Cell Synovial Sarcoma

MalaCards based summary : Epithelioid Cell Synovial Sarcoma, also known as synovial sarcoma, epithelioid cell, is related to sarcoma and pediculus humanus capitis infestation. An important gene associated with Epithelioid Cell Synovial Sarcoma is SSX1 (SSX Family Member 1), and among its related pathways/superpathways is Transcriptional misregulation in cancer. The drugs Doxorubicin and Ifosfamide have been mentioned in the context of this disorder. Related phenotype is Increased shRNA abundance (Z-score > 2).

Related Diseases for Epithelioid Cell Synovial Sarcoma

Diseases related to Epithelioid Cell Synovial Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 sarcoma 10.0
2 pediculus humanus capitis infestation 9.7 SSX1 SSX2B
3 large cell carcinoma 9.6 SSX1 SSX2B
4 sick building syndrome 9.6 SSX1 SSX2B
5 gestational choriocarcinoma 9.5 SSX1 SSX2B
6 spermatogenic failure 13 9.4 SSX1 SSX2B
7 hypohidrosis 9.2 SSX1 SSX2B

Graphical network of the top 20 diseases related to Epithelioid Cell Synovial Sarcoma:



Diseases related to Epithelioid Cell Synovial Sarcoma

Symptoms & Phenotypes for Epithelioid Cell Synovial Sarcoma

GenomeRNAi Phenotypes related to Epithelioid Cell Synovial Sarcoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.4 SSX2B
2 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.4 SSX1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.4 SSX1 SSX2B
4 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.4 SSX2B
5 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.4 SSX1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.4 SSX2B
7 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.4 SSX2B
8 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.4 SSX1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.4 SSX1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-76 9.4 SSX2B
11 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.4 SSX2B
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 9.35 SSX2B
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 9.35 SSX2B
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-206 9.35 SSX1
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.35 SSX1 SSX2B

Drugs & Therapeutics for Epithelioid Cell Synovial Sarcoma

Drugs for Epithelioid Cell Synovial Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 59)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
3
Mechlorethamine Approved Phase 3,Phase 2,Phase 1 51-75-2 4033
4
Lenograstim Approved Phase 3,Phase 2 135968-09-1
5
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 498142 38904
6
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
7
Dactinomycin Approved Phase 3,Phase 2 50-76-0 2019 457193
8
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
9
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
10
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
11
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
12
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
13 Alkylating Agents Phase 3,Phase 2,Phase 1
14 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
15 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
16 Isophosphamide mustard Phase 3,Phase 2,Phase 1
17 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
18 Anti-Infective Agents Phase 3,Phase 2
19 Antimitotic Agents Phase 3,Phase 2
20 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
21 Antirheumatic Agents Phase 3,Phase 2
22 Etoposide phosphate Phase 3,Phase 2
23 Immunosuppressive Agents Phase 3,Phase 2
24 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
25
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
26
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
27
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
28
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
29
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
30
Gemcitabine Approved Phase 2 95058-81-4 60750
31
Everolimus Approved Phase 2 159351-69-6 6442177
32
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
33
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
34
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
35
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
36
Nicotinamide Approved, Nutraceutical Phase 2 98-92-0 936
37 Micronutrients Phase 2
38 Nicotinic Acids Phase 2
39 Protein Kinase Inhibitors Phase 2,Phase 1
40 Trace Elements Phase 2
41 Vitamin B Complex Phase 2
42 Vitamins Phase 2
43 Angiogenesis Inhibitors Phase 2
44 Angiogenesis Modulating Agents Phase 2
45 Imatinib Mesylate Phase 1, Phase 2 123596
46 Antibodies Phase 2,Phase 1
47 Antibodies, Monoclonal Phase 2,Phase 1
48 Immunoglobulins Phase 2,Phase 1
49 Antimetabolites Phase 2
50 Antimetabolites, Antineoplastic Phase 2

Interventional clinical trials:

(show all 26)

id Name Status NCT ID Phase Drugs
1 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
3 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
4 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
5 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
6 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
7 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
8 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
9 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
10 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
11 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
12 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
13 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
14 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
15 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
16 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
17 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
18 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
19 A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma Recruiting NCT02601950 Phase 2 Tazemetostat
20 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
21 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Active, not recruiting NCT01614795 Phase 2 temsirolimus
22 Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma Completed NCT00720174 Phase 1 Doxorubicin Hydrochloride
23 Liposomal Doxorubicin Plus Ifosfamide in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00030784 Phase 1 ifosfamide;pegylated liposomal doxorubicin hydrochloride
24 Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery Recruiting NCT03009201 Phase 1 Doxorubicin;Ribociclib
25 Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas Completed NCT01567046
26 PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma Active, not recruiting NCT00346125 doxorubicin hydrochloride;ifosfamide;pegylated liposomal doxorubicin hydrochloride

Search NIH Clinical Center for Epithelioid Cell Synovial Sarcoma

Genetic Tests for Epithelioid Cell Synovial Sarcoma

Anatomical Context for Epithelioid Cell Synovial Sarcoma

Publications for Epithelioid Cell Synovial Sarcoma

Variations for Epithelioid Cell Synovial Sarcoma

Expression for Epithelioid Cell Synovial Sarcoma

Search GEO for disease gene expression data for Epithelioid Cell Synovial Sarcoma.

Pathways for Epithelioid Cell Synovial Sarcoma

Pathways related to Epithelioid Cell Synovial Sarcoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 10.88 SSX1 SSX2B

GO Terms for Epithelioid Cell Synovial Sarcoma

Biological processes related to Epithelioid Cell Synovial Sarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 negative regulation of nucleic acid-templated transcription GO:1903507 8.62 SSX1 SSX2B

Molecular functions related to Epithelioid Cell Synovial Sarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleic acid binding GO:0003676 8.96 SSX1 SSX2B
2 transcription corepressor activity GO:0003714 8.62 SSX1 SSX2B

Sources for Epithelioid Cell Synovial Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....